U.S. STOCKS ON THE MOVE-Sinclair Broadcast, Virgin Galactic, Tesla
Brief: BiomX Reports Topline Results Of Phase 2 Cosmetic Acne Study
BiomX Inc: Down on underwhelming acne treatment efficacy data
Brief: Biomx Announces Agreement With Maruho Co For Atopic Dermatitis Product Candidate Bx005
AMEX RESUMED BIOMX INC UNT
AMEX HALT ADDITIONAL INFORMATION LAST 6.78740
Brief: Biomx Reports Q2 Loss Per Share Of $0.30
Brief: BiomX Inc. Announces $15 Mln Registered Direct Offering
Brief: BiomX Presents Preclinical Results With BX005 For Atopic Dermatitis
Brief: Biomx To Present Preclinical Results With Bx004 In Cystic Fibrosis At The 44Th European Cystic Fibrosis Conference
Brief: Biomx Reports First Quarter 2021 Financial Results And Provides Business Updates
Brief: Biomx Reports Phase 2 Study Of Newly Selected Phage Cocktail Candidate Bx005 In Atopic Dermatitis Expected To Initiate In H2 2021
Brief: BiomX Announces Dosing Of First Subject In Phase 2 Study Of BX001
Brief: Biomx Announces Positive Results Of A Phase 1A Pharmacokinetic Study For Inflammatory Bowel Disease/Primary Sclerosing Cholangitis Evaluating Delivery Of Oral BX002 Phage Therapy
AMEX RESUMED BIOMX INC UNT
AMEX HALT ADDITIONAL INFORMATION LAST 8.15000
BiomX Inc: Rises on therapy to target bacteria in colorectal cancer patients
Brief: Biomx Announces Preclinical Results Of Analysis Of Patient Samples And Engineering Of Phage For Therapeutic Applications In Colorectal Cancer
Brief: Biomx Inc Files For Mixed Shelf Of Up To $150 Million